68ga-ny104
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 25, 2021 (NCT05728515)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06613269 | Phase 2 | Mar 27, 2024 | Chinese Academy of Medical Sciences, Peking University |
| NCT05638256 | Early Phase 1 (Phase 1) | Oct 10, 2022 | Jiangnan University |
| NCT05691881 | Early Phase 1 (Phase 1) | Sep 28, 2022 | Jiangnan University |
| NCT05728515 | Early Phase 1 (Phase 1) | Dec 25, 2021 | Chinese Academy of Medical Sciences, Peking University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Jiangnan University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Peking University | Academic/Hospital | 2 | 0 | 2 | 2021 |
3 organizations
Page 1 / 1